In the U.S., positive results of the use of Remdesivir drug against Covid-19 as the US National Institute of Allergy and Infectious Diseases (NIAID) stated.
“According to a preliminary data analysis from a randomized, controlled trial involving 1,063 patients, it is established that patients who received remdesivir had a 31% faster time to recovery,” the message said.
The trial has started on February 21 and 68 centers in the U.S., Europe and Asia joined it. 1,063 patients with coronavirus participated in it, including those who needed extra oxygen and artificial lung ventilation.
The recovery of patients who received Remdesivir took place in 11 days averagely, while in other cases – 15 days (31% difference). Besides, a low case fatality rate was spotted in the group, which received Remdesivir – 8% against 11.6% in other cases.
It is stated that Remdesivir developed by Gilead Sciences Inc. is the investigational broad-spectrum antiviral treatment administered via daily infusion for 10 days. It showed suggestive results on animals during treatment of SARS-CoV-2 and it was researched in different clinical trials.
As we reported, in China, the research showed that after the recovery of a patient, the coronavirus may lurk deep in the lungs and it cannot be determined by usual test methods.